Published in Biotech Law Weekly, April 7th, 2006
Previously Arius announced that it had received a Notice of Allowance in October 2005.
The patent covers the antibody molecule, various uses of the antibody, its derivatives, and a method for using it, and other similar antibodies, to treat cancers such as prostate and breast cancer. Arius has several additional patent applications pending that will continue to enhance the value of this and other important antibody assets.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.